When it comes to NVDA… “acceleration cycles” are the key

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

Claire Poll Biography and Net Worth

General Counsel of Verona Pharma

From September 2015 to August 2016, Ms Poll served as an advisor to us, where she advised on legal, strategic, corporate, and financing matters. She also served as an Executive Director on our board of directors from September 2006 until September 2016. Ms Poll received a Bachelor of Arts, a Bachelor of Laws and a Bachelor of Jurisprudence from the University of Western Australia and a Diploma in Applied Finance and Investment.

What is Claire Poll's net worth?: The estimated net worth of Claire Poll is at least $74.10 million as of August 7th, 2023. Ms. Poll owns 1,907,367 shares of Verona Pharma stock worth more than $74,101,208 as of November 21st. This net worth estimate does not reflect any other assets that Ms. Poll may own. Learn More about Claire Poll's net worth.
How do I contact Claire Poll?: The corporate mailing address for Ms. Poll and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Claire Poll's contact information.
Has Claire Poll been buying or selling shares of Verona Pharma?: Claire Poll has not been actively trading shares of Verona Pharma over the course of the past ninety days. Most recently, Claire Poll sold 1,512 shares of the business's stock in a transaction on Monday, August 7th. The shares were sold at an average price of $2.47, for a transaction totalling $3,734.64. Following the completion of the sale, the general counsel now directly owns 1,907,367 shares of the company's stock, valued at $4,711,196.49. Learn More on Claire Poll's trading history.
Who are Verona Pharma's active insiders?: Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.
Are insiders buying or selling shares of Verona Pharma?: In the last year, Verona Pharma insiders bought shares 1 times. They purchased a total of 39,360 shares worth more than $188,928.00. In the last year, insiders at the sold shares 13 times. They sold a total of 1,178,192 shares worth more than $5,075,998.08. The most recent insider tranaction occured on November, 11th when CEO David Zaccardelli sold 2,400 shares worth more than $12,000.00. Insiders at Verona Pharma own 4.8% of the company. Learn More about insider trades at Verona Pharma.
Information on this page was last updated on 11/11/2024.

Claire Poll Insider Trading History at Verona Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/7/2023	Sell	1,512	$2.47	$3,734.64	1,907,367
8/3/2023	Sell	20,608	$2.54	$52,344.32	1,935,231
8/1/2023	Sell	18,608	$2.68	$49,869.44	1,968,783
5/1/2023	Sell	80,376	$2.58	$207,370.08	1,979,063
2/1/2023	Sell	152,000	$2.59	$393,680.00	774,256
12/22/2022	Sell	240,000	$2.69	$645,600.00	774,256

Claire Poll Buying and Selling Activity at Verona Pharma

Verona Pharma Company Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Today's Range

Now: $38.85

$37.61

$39.33

50 Day Range

MA: $33.12

$27.64

$39.87

2 Week Range

Now: $38.85

$11.39

$40.13

Volume

1,155,655 shs

Average Volume

1,099,138 shs

Market Capitalization

$3.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42

Download Our Tesla Ebook For Free

From DTI | Ad

Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.